Pharmaceutica Analytica Acta

Mucoadhesive biomaterials for targeted drug delivery

5^th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems

March 16-18, 2015 Crowne Plaza, Dubai, UAE

Flavia Laffleur

Posters & Accepted Abstracts: Pharm Anal Acta

Abstract:

The aim of this study was to develop and evaluate a more effective mucoadhesive thiomer for buccal drug delivery systems. Therefore, 2-iminothiolane was covalently attached to chitosan backbone. Following, a preactivation step followed, mediated by 6,6?dithionicotinamide (6,6-DTNA), thiol groups were modified by disulfide bonds formation. Mucoadhesion studies were performed on mucosa. Additionally, water binding capacity, disintegration and cytotoxicity studies were accomplished. Chitosan-thiobutylamidine-mercaptonicotinamid (Ch-TBA-MNA) displayed 1.8-fold higher stability and 1.6-fold higher mucoadhesive properties, respectively. Due to these results preactivated thiomers exhibits an improved stability and enhanced mucoadhesive properties. Within the present study a preactivated thiolated chitosan matrix for non-invasive drug delivery was developed. The covalent attachment of preactivated thiol groups to thiolated chitosan leads to strongly improved mucoadhesive properties of the thiolated polymer, which is verified by rotating cylinder studies on freshly excised porcine mucosa and by the increase in the total work of adhesion in tensile studies. Because of this slightly chemical modification the swelling behavior of thiolated chitosan could also be improved. This property might be of considerable advantage for applications requiring mucoadhesive and long lasting properties. These features should render preactivated thiolated chitosan as useful therapeutic excipient for various dosage forms providing an improved stability and a prolonged residence time on mucosal tissues. The preactivated thiolated chitosan described within this study raises the bar according to its high mucoadhesive potential as therapeutic agent.

Biography :

Flavia Laffleur is pursuing her PhD from University of Innsbruck at the Department of pharmaceutical technology. She has published two papers in reputed journals.